

I hereby certify that this correspondence is being electronically transmitted to the United States Patent and Trademark Office on the date shown below:

AMENDMENT UNDER 37 CFR, 1.111
Examining Group 1609
Patent Application
Docket No. GJE-7147

December 20, 2007

David Saliwanchik

David R. Saliwanchik, Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Sahar Javanmard
Art Unit : 1609
Applicants : Robin Mark Bannister *et al.*
Serial No. : 10/517,881
Filed : December 13, 2004
Conf. No. : 1605
For : Use of Nefopam for the Treatment of Nausea or Emesis

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA. 22313-1450

AMENDMENT UNDER 37 CFR §1.111

Sir:

An Extension of Time is being authorized with the electronic filing of this paper.

In response to the Office Action dated July 25, 2007, please amend the above-referenced application as follows:

Amendments to the Specification begin on page 2 of this paper.

Amendments to the Claims are reflected in the listing of claims beginning on page 3 of this paper.

Remarks/Arguments follow the amendment section of this paper.